Additionally, a significant number of drugs targeting neuro-cancer signaling pathways are currently under development, including NGF (Nerve Growth Factor) inhibitors, Glutamate release inhibitors, and Voltage-Gated Sodium Channel (VGSC) inhibitors (115). Here, NGF is linked to cancer.